WO2021150713A3 - Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e - Google Patents

Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e Download PDF

Info

Publication number
WO2021150713A3
WO2021150713A3 PCT/US2021/014360 US2021014360W WO2021150713A3 WO 2021150713 A3 WO2021150713 A3 WO 2021150713A3 US 2021014360 W US2021014360 W US 2021014360W WO 2021150713 A3 WO2021150713 A3 WO 2021150713A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
hervs
immunogenic epitopes
endogenous retroviruses
polypeptide
Prior art date
Application number
PCT/US2021/014360
Other languages
English (en)
Other versions
WO2021150713A2 (fr
Inventor
Jeffrey Schlom
Claudia M. Palena
Renee N. DONAHUE
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2021150713A2 publication Critical patent/WO2021150713A2/fr
Publication of WO2021150713A3 publication Critical patent/WO2021150713A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un épitope agoniste des lymphocytes T cytotoxiques humains de rétrovirus endogènes humains H, K et E, qui peut être utilisé en tant que peptide, polypeptide (protéine) et/ou dans des vaccins ou une autre composition utilisable en vue de la prévention ou du traitement du cancer. L'invention concerne en outre un acide nucléique codant pour le peptide ou le polypeptide (protéine), un vecteur comprenant l'acide nucléique, une cellule comprenant le peptide, le polypeptide (protéine), l'acide nucléique ou le vecteur et des compositions de ceux-ci.
PCT/US2021/014360 2020-01-21 2021-01-21 Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e WO2021150713A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062963856P 2020-01-21 2020-01-21
US62/963,856 2020-01-21

Publications (2)

Publication Number Publication Date
WO2021150713A2 WO2021150713A2 (fr) 2021-07-29
WO2021150713A3 true WO2021150713A3 (fr) 2021-10-07

Family

ID=74626199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/014360 WO2021150713A2 (fr) 2020-01-21 2021-01-21 Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e

Country Status (1)

Country Link
WO (1) WO2021150713A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144231A1 (fr) * 2022-01-25 2023-08-03 Ervaccine Technologies Nouvelle méthode d'identification d'épitopes dérivés d'herv
CN117591812B (zh) * 2024-01-18 2024-04-26 中国人民解放军总医院第二医学中心 一种智能电子听诊器电信号降噪处理优化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040720A2 (fr) * 2000-11-20 2002-05-23 Diadexus, Inc. Compositions et procedes pour une utilisation relative a des genes et a des proteines specifiques des ovaires
EP2340851A1 (fr) * 2008-09-18 2011-07-06 Keio University Procédé de diagnostic et procédé thérapeutique pour le cancer
WO2014004385A2 (fr) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Vaccins anticancéreux

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
IE912535A1 (en) 1990-07-27 1992-01-29 Res Dev Foundation Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
DK1335987T4 (en) 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
JP5052893B2 (ja) 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040720A2 (fr) * 2000-11-20 2002-05-23 Diadexus, Inc. Compositions et procedes pour une utilisation relative a des genes et a des proteines specifiques des ovaires
EP2340851A1 (fr) * 2008-09-18 2011-07-06 Keio University Procédé de diagnostic et procédé thérapeutique pour le cancer
WO2014004385A2 (fr) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Vaccins anticancéreux

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTINA S MULLINS ET AL: "Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-Hencoding strong CTL epitopes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 7, 21 December 2011 (2011-12-21), pages 1093 - 1100, XP035074377, ISSN: 1432-0851, DOI: 10.1007/S00262-011-1183-3 *
DATABASE UniProt [online] 27 January 2005 (2005-01-27), XP002802755, Database accession no. UNIPARC:UPI00004C6414 *
DATABASE UniProt [online] 7 September 2019 (2019-09-07), XP002802754, Database accession no. UNIPARC:UPI001163D5E4 *

Also Published As

Publication number Publication date
WO2021150713A2 (fr) 2021-07-29

Similar Documents

Publication Publication Date Title
EP2626420A3 (fr) Polynucléotides codant des épitopes HTERT restreints au CMH de classe I HLA-B7, leurs analogues ou polyépitopes
WO2021150713A3 (fr) Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e
PH12019500280A1 (en) Trimer stabilizing hiv envelope protein mutations
WO2015061416A3 (fr) Épitopes agonistes de hla-a24 de l'oncoprotéine muc1-c, compositions en contenant et leurs procédés d'utilisation
DK1461073T3 (da) Peptidagonister til prostataspecifikt antigen og anvendelser heraf
WO2019197567A3 (fr) Peptides antigéniques pour la prévention et le traitement du cancer
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
JP2019525753A5 (fr)
WO2008020335A8 (fr) Compositions immunogènes pour streptococcus agalactiae
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
EP3103471A3 (fr) Antigènes acinetobacter baumanii et leurs utilisations
MX2020000414A (es) Composicion de vacuna de neoantigeno para el tratamiento del cancer.
PL1951283T3 (pl) Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
EP1613345A4 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2019123018A3 (fr) Vaccin contre lassa
WO2022036142A3 (fr) Néoantigènes ras et leurs utilisations
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
WO2021019235A3 (fr) Composition antigénique d'hantavirus
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
WO2023196634A3 (fr) Vaccins et procédés associés
WO2023069933A3 (fr) Peptides et récepteurs de lymphocytes t modifiés ciblant l'antigène ndc80 et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21705774

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21705774

Country of ref document: EP

Kind code of ref document: A2